nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—CITED2—bone cancer	0.0318	0.0962	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.0187	0.0566	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—FEV—bone cancer	0.00941	0.0284	CbGpPWpGaD
Gliclazide—VEGFA—S1P3 pathway—GNA11—bone cancer	0.00888	0.0268	CbGpPWpGaD
Gliclazide—VEGFA—Glypican 1 network—TGFBR2—bone cancer	0.00667	0.0202	CbGpPWpGaD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00632	0.0191	CbGpPWpGaD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00576	0.0174	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—FOLR1—bone cancer	0.00562	0.017	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00551	0.0166	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.0051	0.0154	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IL3—bone cancer	0.00478	0.0144	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.0046	0.0139	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—TGFBR2—bone cancer	0.00446	0.0135	CbGpPWpGaD
Gliclazide—VEGFA—S1P1 pathway—PTGS2—bone cancer	0.00444	0.0134	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CDK4—bone cancer	0.0042	0.0127	CbGpPWpGaD
Gliclazide—ABCC8—Regulation of insulin secretion—GNA11—bone cancer	0.00395	0.0119	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—GNA11—bone cancer	0.00383	0.0116	CbGpPWpGaD
Gliclazide—VEGFA—Platelet degranulation—SPARC—bone cancer	0.00383	0.0116	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—BRAF—bone cancer	0.00372	0.0112	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—RB1—bone cancer	0.00365	0.011	CbGpPWpGaD
Gliclazide—VEGFA—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00365	0.011	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—MET—bone cancer	0.00343	0.0104	CbGpPWpGaD
Gliclazide—VEGFA—Beta3 integrin cell surface interactions—PLAU—bone cancer	0.00342	0.0103	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IGF1R—bone cancer	0.0033	0.00998	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—TGFBR2—bone cancer	0.00329	0.00993	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—MMP9—bone cancer	0.00323	0.00977	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—MDM2—bone cancer	0.00312	0.00941	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00311	0.0094	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—GNA11—bone cancer	0.00311	0.00939	CbGpPWpGaD
Gliclazide—VEGFA—Integrins in angiogenesis—IGF1R—bone cancer	0.00309	0.00934	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—IGF1R—bone cancer	0.00305	0.00923	CbGpPWpGaD
Gliclazide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00305	0.00921	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—GNA11—bone cancer	0.00301	0.0091	CbGpPWpGaD
Gliclazide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00293	0.00886	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—KIT—bone cancer	0.00279	0.00842	CbGpPWpGaD
Gliclazide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00278	0.0084	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—BMI1—bone cancer	0.00276	0.00834	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00272	0.00822	CbGpPWpGaD
Gliclazide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00267	0.00808	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00266	0.00805	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—PLAU—bone cancer	0.00249	0.00752	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00248	0.00749	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—PLAU—bone cancer	0.00243	0.00734	CbGpPWpGaD
Gliclazide—Glipizide—CYP3A4—bone cancer	0.00234	0.672	CrCbGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.00231	0.00697	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00224	0.00678	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00219	0.00662	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—EGFR—bone cancer	0.00213	0.00643	CbGpPWpGaD
Gliclazide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00209	0.00633	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—bone cancer	0.00198	0.00599	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.00196	0.00592	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00191	0.00577	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00191	0.00577	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00188	0.00569	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00182	0.00549	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—TP53—bone cancer	0.00179	0.0054	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00174	0.00525	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—EGFR—bone cancer	0.00174	0.00525	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.0017	0.00513	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.00163	0.00494	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.0016	0.00482	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00158	0.00478	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.00156	0.00472	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.00155	0.00469	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00155	0.00469	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—DHFR—bone cancer	0.00154	0.00466	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—JUN—bone cancer	0.00148	0.00447	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—MMP9—bone cancer	0.00148	0.00446	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.00144	0.00436	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP2—bone cancer	0.00144	0.00436	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00141	0.00426	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—SPARC—bone cancer	0.00135	0.00408	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—EZH2—bone cancer	0.00134	0.00405	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00132	0.004	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—EGFR—bone cancer	0.00129	0.0039	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00129	0.00389	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—IGF1R—bone cancer	0.00128	0.00386	CbGpPWpGaD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00127	0.00383	CbGpPWpGaD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00125	0.00378	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00125	0.00377	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.00118	0.00358	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00115	0.00349	CbGpPWpGaD
Gliclazide—Glyburide—CYP3A4—bone cancer	0.00114	0.328	CrCbGaD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00114	0.00344	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NDUFA12—bone cancer	0.00113	0.00341	CbGpPWpGaD
Gliclazide—Gastritis—Doxorubicin—bone cancer	0.0011	0.00165	CcSEcCtD
Gliclazide—Pain—Cisplatin—bone cancer	0.0011	0.00165	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—NDUFA12—bone cancer	0.00109	0.00331	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00109	0.00164	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—MMP9—bone cancer	0.00108	0.00328	CbGpPWpGaD
Gliclazide—Renal failure—Methotrexate—bone cancer	0.00108	0.00163	CcSEcCtD
Gliclazide—Abdominal distension—Doxorubicin—bone cancer	0.00108	0.00162	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—bone cancer	0.00108	0.00162	CcSEcCtD
Gliclazide—Conjunctivitis—Methotrexate—bone cancer	0.00107	0.00161	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—bone cancer	0.00107	0.00161	CcSEcCtD
Gliclazide—Sweating—Methotrexate—bone cancer	0.00106	0.00159	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—bone cancer	0.00106	0.00159	CcSEcCtD
Gliclazide—Feeling abnormal—Cisplatin—bone cancer	0.00106	0.00159	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—bone cancer	0.00105	0.00158	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00105	0.00317	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—GSTP1—bone cancer	0.00104	0.00316	CbGpPWpGaD
Gliclazide—Hyperglycaemia—Epirubicin—bone cancer	0.00104	0.00157	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—bone cancer	0.00104	0.00157	CcSEcCtD
Gliclazide—Hepatobiliary disease—Methotrexate—bone cancer	0.00104	0.00157	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—bone cancer	0.00104	0.00156	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—bone cancer	0.00104	0.00156	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—bone cancer	0.00103	0.00155	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—bone cancer	0.00103	0.00155	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—RB1—bone cancer	0.00103	0.00311	CbGpPWpGaD
Gliclazide—Agranulocytosis—Methotrexate—bone cancer	0.00103	0.00155	CcSEcCtD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00103	0.0031	CbGpPWpGaD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00102	0.00154	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—bone cancer	0.00102	0.00153	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—bone cancer	0.00101	0.00152	CcSEcCtD
Gliclazide—Body temperature increased—Cisplatin—bone cancer	0.00101	0.00152	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—bone cancer	0.00101	0.00152	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—bone cancer	0.00101	0.00151	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—bone cancer	0.001	0.00151	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—bone cancer	0.001	0.00151	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000996	0.0015	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—bone cancer	0.00099	0.00149	CcSEcCtD
Gliclazide—Sweating—Epirubicin—bone cancer	0.00099	0.00149	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—bone cancer	0.000989	0.00299	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—MET—bone cancer	0.000985	0.00298	CbGpPWpGaD
Gliclazide—Pharyngitis—Methotrexate—bone cancer	0.000983	0.00148	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000981	0.00296	CbGpPWpGaD
Gliclazide—Photosensitivity reaction—Doxorubicin—bone cancer	0.000978	0.00147	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—bone cancer	0.000976	0.00147	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—bone cancer	0.000975	0.00146	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—bone cancer	0.000974	0.00146	CcSEcCtD
Gliclazide—Sinusitis—Epirubicin—bone cancer	0.000969	0.00146	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—bone cancer	0.000966	0.00145	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—bone cancer	0.000963	0.00145	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—bone cancer	0.000961	0.00144	CcSEcCtD
Gliclazide—Drowsiness—Doxorubicin—bone cancer	0.000955	0.00144	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—bone cancer	0.000954	0.00143	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000947	0.00142	CcSEcCtD
Gliclazide—Hypersensitivity—Cisplatin—bone cancer	0.000945	0.00142	CcSEcCtD
Gliclazide—Bradycardia—Epirubicin—bone cancer	0.000944	0.00142	CcSEcCtD
Gliclazide—Renal failure—Doxorubicin—bone cancer	0.000939	0.00141	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—bone cancer	0.000936	0.00141	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000936	0.00141	CcSEcCtD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000936	0.00283	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NT5C3A—bone cancer	0.000936	0.00283	CbGpPWpGaD
Gliclazide—Jaundice—Doxorubicin—bone cancer	0.000931	0.0014	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—bone cancer	0.000929	0.0014	CcSEcCtD
Gliclazide—Urinary tract infection—Doxorubicin—bone cancer	0.000929	0.0014	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—bone cancer	0.000929	0.0014	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—bone cancer	0.000927	0.00139	CcSEcCtD
Gliclazide—Eye disorder—Methotrexate—bone cancer	0.000926	0.00139	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—bone cancer	0.000923	0.00139	CcSEcCtD
Gliclazide—Hypoaesthesia—Epirubicin—bone cancer	0.000922	0.00139	CcSEcCtD
Gliclazide—Asthenia—Cisplatin—bone cancer	0.00092	0.00138	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—bone cancer	0.00092	0.00138	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—bone cancer	0.000916	0.00138	CcSEcCtD
Gliclazide—Oedema peripheral—Epirubicin—bone cancer	0.000913	0.00137	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—NT5C3A—bone cancer	0.000907	0.00274	CbGpPWpGaD
Gliclazide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000903	0.00136	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—bone cancer	0.000901	0.00135	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—bone cancer	0.000896	0.00135	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—bone cancer	0.000893	0.00134	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—bone cancer	0.000891	0.00134	CcSEcCtD
Gliclazide—Chills—Methotrexate—bone cancer	0.000889	0.00134	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000878	0.00265	CbGpPWpGaD
Gliclazide—Diarrhoea—Cisplatin—bone cancer	0.000877	0.00132	CcSEcCtD
Gliclazide—Erythema multiforme—Epirubicin—bone cancer	0.000876	0.00132	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—SPARC—bone cancer	0.000875	0.00265	CbGpPWpGaD
Gliclazide—Bradycardia—Doxorubicin—bone cancer	0.000873	0.00131	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—BRAF—bone cancer	0.000872	0.00263	CbGpPWpGaD
Gliclazide—Mental disorder—Methotrexate—bone cancer	0.000868	0.0013	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—bone cancer	0.000866	0.0013	CcSEcCtD
Gliclazide—Tinnitus—Epirubicin—bone cancer	0.000864	0.0013	CcSEcCtD
Gliclazide—Erythema—Methotrexate—bone cancer	0.000862	0.0013	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—bone cancer	0.000862	0.0013	CcSEcCtD
Gliclazide—Flushing—Epirubicin—bone cancer	0.00086	0.00129	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—bone cancer	0.00086	0.00129	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—bone cancer	0.000858	0.00129	CcSEcCtD
Gliclazide—Hypoaesthesia—Doxorubicin—bone cancer	0.000853	0.00128	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—bone cancer	0.000851	0.00128	CcSEcCtD
Gliclazide—Oedema peripheral—Doxorubicin—bone cancer	0.000845	0.00127	CcSEcCtD
Gliclazide—Back pain—Methotrexate—bone cancer	0.000834	0.00125	CcSEcCtD
Gliclazide—Chills—Epirubicin—bone cancer	0.000832	0.00125	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—bone cancer	0.000828	0.00124	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—bone cancer	0.000826	0.00124	CcSEcCtD
Gliclazide—Vomiting—Cisplatin—bone cancer	0.000815	0.00122	CcSEcCtD
Gliclazide—Mental disorder—Epirubicin—bone cancer	0.000812	0.00122	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—bone cancer	0.000811	0.00122	CcSEcCtD
Gliclazide—Rash—Cisplatin—bone cancer	0.000808	0.00121	CcSEcCtD
Gliclazide—Dermatitis—Cisplatin—bone cancer	0.000808	0.00121	CcSEcCtD
Gliclazide—Erythema—Epirubicin—bone cancer	0.000807	0.00121	CcSEcCtD
Gliclazide—Malnutrition—Epirubicin—bone cancer	0.000807	0.00121	CcSEcCtD
Gliclazide—Eye disorder—Doxorubicin—bone cancer	0.000801	0.0012	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—GNA11—bone cancer	0.000801	0.00242	CbGpPWpGaD
Gliclazide—Ill-defined disorder—Methotrexate—bone cancer	0.0008	0.0012	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—bone cancer	0.0008	0.0012	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—bone cancer	0.000797	0.0012	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—bone cancer	0.000796	0.0012	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—bone cancer	0.000795	0.00119	CcSEcCtD
Gliclazide—Tension—Epirubicin—bone cancer	0.000792	0.00119	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—bone cancer	0.000784	0.00118	CcSEcCtD
Gliclazide—Back pain—Epirubicin—bone cancer	0.00078	0.00117	CcSEcCtD
Gliclazide—Malaise—Methotrexate—bone cancer	0.000777	0.00117	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—bone cancer	0.000772	0.00116	CcSEcCtD
Gliclazide—Chills—Doxorubicin—bone cancer	0.000769	0.00116	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—bone cancer	0.000766	0.00115	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000763	0.00231	CbGpPWpGaD
Gliclazide—Nausea—Cisplatin—bone cancer	0.000762	0.00114	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CDK4—bone cancer	0.000757	0.00229	CbGpPWpGaD
Gliclazide—Cough—Methotrexate—bone cancer	0.000752	0.00113	CcSEcCtD
Gliclazide—Mental disorder—Doxorubicin—bone cancer	0.000751	0.00113	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—bone cancer	0.000749	0.00112	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—bone cancer	0.000747	0.00112	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—bone cancer	0.000747	0.00112	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—bone cancer	0.000747	0.00112	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—bone cancer	0.000746	0.00112	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—JUN—bone cancer	0.000743	0.00225	CbGpPWpGaD
Gliclazide—Agitation—Epirubicin—bone cancer	0.000741	0.00111	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—bone cancer	0.000736	0.00111	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—bone cancer	0.000734	0.0011	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—bone cancer	0.000734	0.0011	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—bone cancer	0.000734	0.0011	CcSEcCtD
Gliclazide—Tension—Doxorubicin—bone cancer	0.000733	0.0011	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000729	0.0011	CcSEcCtD
Gliclazide—Malaise—Epirubicin—bone cancer	0.000728	0.00109	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000727	0.0022	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL3—bone cancer	0.000726	0.00219	CbGpPWpGaD
Gliclazide—Discomfort—Methotrexate—bone cancer	0.000725	0.00109	CcSEcCtD
Gliclazide—Nervousness—Doxorubicin—bone cancer	0.000725	0.00109	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—bone cancer	0.000722	0.00109	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—bone cancer	0.000722	0.00108	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—bone cancer	0.000713	0.00107	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—bone cancer	0.000709	0.00107	CcSEcCtD
Gliclazide—Loss of consciousness—Epirubicin—bone cancer	0.000709	0.00107	CcSEcCtD
Gliclazide—Cough—Epirubicin—bone cancer	0.000704	0.00106	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—BRAF—bone cancer	0.000702	0.00212	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000701	0.00212	CbGpPWpGaD
Gliclazide—Convulsion—Epirubicin—bone cancer	0.000699	0.00105	CcSEcCtD
Gliclazide—Infection—Methotrexate—bone cancer	0.000699	0.00105	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—bone cancer	0.000697	0.00105	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—bone cancer	0.000693	0.00104	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—bone cancer	0.00069	0.00104	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—bone cancer	0.00069	0.00104	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—bone cancer	0.000689	0.00104	CcSEcCtD
Gliclazide—Arthralgia—Epirubicin—bone cancer	0.000687	0.00103	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—bone cancer	0.000687	0.00103	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—bone cancer	0.000687	0.00103	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—bone cancer	0.000686	0.00103	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—bone cancer	0.000685	0.00103	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—bone cancer	0.000683	0.00103	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000682	0.00102	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—BRAF—bone cancer	0.00068	0.00206	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Methotrexate—bone cancer	0.00068	0.00102	CcSEcCtD
Gliclazide—Discomfort—Epirubicin—bone cancer	0.000679	0.00102	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—bone cancer	0.000673	0.00101	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—bone cancer	0.000672	0.00101	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—bone cancer	0.000668	0.001	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—bone cancer	0.000664	0.000998	CcSEcCtD
Gliclazide—Palpitations—Doxorubicin—bone cancer	0.00066	0.000991	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—RB1—bone cancer	0.000658	0.00199	CbGpPWpGaD
Gliclazide—Hypotension—Methotrexate—bone cancer	0.000657	0.000988	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—bone cancer	0.000656	0.000986	CcSEcCtD
Gliclazide—Infection—Epirubicin—bone cancer	0.000654	0.000983	CcSEcCtD
Gliclazide—Cough—Doxorubicin—bone cancer	0.000651	0.000979	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000649	0.00196	CbGpPWpGaD
Gliclazide—Convulsion—Doxorubicin—bone cancer	0.000647	0.000972	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—bone cancer	0.000646	0.00097	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—bone cancer	0.000645	0.000969	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—bone cancer	0.000645	0.000968	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MET—bone cancer	0.000643	0.00194	CbGpPWpGaD
Gliclazide—Tachycardia—Epirubicin—bone cancer	0.000643	0.000966	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000641	0.000963	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—bone cancer	0.00064	0.000961	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—bone cancer	0.000637	0.000956	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—bone cancer	0.000636	0.000956	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—bone cancer	0.000636	0.000955	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—bone cancer	0.000636	0.000955	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—bone cancer	0.000636	0.000955	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—JUN—bone cancer	0.000635	0.00192	CbGpPWpGaD
Gliclazide—Anxiety—Doxorubicin—bone cancer	0.000633	0.000952	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000632	0.00191	CbGpPWpGaD
Gliclazide—Paraesthesia—Methotrexate—bone cancer	0.000632	0.000949	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000631	0.000948	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—bone cancer	0.000628	0.000943	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—bone cancer	0.000627	0.000943	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—bone cancer	0.000626	0.00094	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—bone cancer	0.000622	0.000934	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—bone cancer	0.000619	0.000931	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—bone cancer	0.000615	0.000924	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—bone cancer	0.000614	0.000923	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000607	0.000913	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—bone cancer	0.000607	0.000911	CcSEcCtD
Gliclazide—Infection—Doxorubicin—bone cancer	0.000605	0.000909	CcSEcCtD
Gliclazide—Pain—Methotrexate—bone cancer	0.000602	0.000904	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.0006	0.000901	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.0006	0.00181	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000599	0.00181	CbGpPWpGaD
Gliclazide—Nervous system disorder—Doxorubicin—bone cancer	0.000597	0.000898	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—bone cancer	0.000597	0.000896	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—bone cancer	0.000596	0.000895	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—bone cancer	0.000595	0.000893	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000592	0.00179	CbGpPWpGaD
Gliclazide—Skin disorder—Doxorubicin—bone cancer	0.000592	0.000889	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—bone cancer	0.000591	0.000888	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—bone cancer	0.000589	0.000885	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—MDM2—bone cancer	0.000588	0.00178	CbGpPWpGaD
Gliclazide—Dyspnoea—Epirubicin—bone cancer	0.000587	0.000882	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—bone cancer	0.000585	0.00088	CcSEcCtD
Gliclazide—Feeling abnormal—Methotrexate—bone cancer	0.00058	0.000871	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—bone cancer	0.00058	0.000871	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—bone cancer	0.000575	0.000864	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—MDM2—bone cancer	0.00057	0.00172	CbGpPWpGaD
Gliclazide—Hypotension—Doxorubicin—bone cancer	0.000569	0.000855	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000568	0.000854	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—bone cancer	0.000568	0.000853	CcSEcCtD
Gliclazide—Constipation—Epirubicin—bone cancer	0.000563	0.000846	CcSEcCtD
Gliclazide—Pain—Epirubicin—bone cancer	0.000563	0.000846	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—MDM2—bone cancer	0.000561	0.0017	CbGpPWpGaD
Gliclazide—Urticaria—Methotrexate—bone cancer	0.000559	0.00084	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—bone cancer	0.000556	0.000836	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—bone cancer	0.000556	0.000836	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000555	0.000834	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—bone cancer	0.000551	0.000828	CcSEcCtD
Gliclazide—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000548	0.00166	CbGpPWpGaD
Gliclazide—Paraesthesia—Doxorubicin—bone cancer	0.000547	0.000822	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000545	0.00165	CbGpPWpGaD
Gliclazide—Dyspnoea—Doxorubicin—bone cancer	0.000543	0.000816	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—bone cancer	0.000543	0.000815	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—bone cancer	0.000542	0.000814	CcSEcCtD
Gliclazide—Gastrointestinal pain—Epirubicin—bone cancer	0.000538	0.000809	CcSEcCtD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000538	0.00162	CbGpPWpGaD
Gliclazide—Dyspepsia—Doxorubicin—bone cancer	0.000536	0.000806	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—MMP2—bone cancer	0.000536	0.00162	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000526	0.00079	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—bone cancer	0.000525	0.000789	CcSEcCtD
Gliclazide—Urticaria—Epirubicin—bone cancer	0.000523	0.000786	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—bone cancer	0.000521	0.000783	CcSEcCtD
Gliclazide—Pain—Doxorubicin—bone cancer	0.000521	0.000783	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—bone cancer	0.000521	0.000782	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—bone cancer	0.000521	0.000782	CcSEcCtD
Gliclazide—Hypersensitivity—Methotrexate—bone cancer	0.000518	0.000779	CcSEcCtD
Gliclazide—Asthenia—Methotrexate—bone cancer	0.000505	0.000758	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000504	0.00152	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—bone cancer	0.000502	0.000754	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—EGFR—bone cancer	0.000499	0.00151	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Doxorubicin—bone cancer	0.000498	0.000749	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—bone cancer	0.000498	0.000748	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000497	0.0015	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000497	0.0015	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000497	0.0015	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.00049	0.00148	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—JUN—bone cancer	0.000488	0.00147	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—RGS1—bone cancer	0.000486	0.00147	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GRM4—bone cancer	0.000486	0.00147	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—bone cancer	0.000485	0.000729	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—bone cancer	0.000484	0.000727	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—bone cancer	0.000482	0.000724	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—bone cancer	0.000482	0.000724	CcSEcCtD
Gliclazide—Diarrhoea—Methotrexate—bone cancer	0.000481	0.000723	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—PLAU—bone cancer	0.000476	0.00144	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—bone cancer	0.000472	0.00071	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000466	0.00141	CbGpPWpGaD
Gliclazide—Pruritus—Epirubicin—bone cancer	0.000466	0.0007	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000466	0.00141	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—bone cancer	0.000465	0.000699	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.00046	0.00139	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.00046	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MET—bone cancer	0.000459	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CDK4—bone cancer	0.000459	0.00139	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—bone cancer	0.000451	0.000677	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—bone cancer	0.000449	0.000674	CcSEcCtD
Gliclazide—Vomiting—Methotrexate—bone cancer	0.000447	0.000672	CcSEcCtD
Gliclazide—Rash—Methotrexate—bone cancer	0.000444	0.000667	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—bone cancer	0.000443	0.000666	CcSEcCtD
Gliclazide—Headache—Methotrexate—bone cancer	0.000441	0.000662	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—bone cancer	0.000437	0.000657	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—bone cancer	0.000435	0.000654	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—bone cancer	0.000431	0.000648	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000425	0.00128	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GRM1—bone cancer	0.000421	0.00127	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000419	0.00127	CbGpPWpGaD
Gliclazide—Vomiting—Epirubicin—bone cancer	0.000419	0.000629	CcSEcCtD
Gliclazide—Nausea—Methotrexate—bone cancer	0.000418	0.000628	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000417	0.00126	CbGpPWpGaD
Gliclazide—Diarrhoea—Doxorubicin—bone cancer	0.000417	0.000626	CcSEcCtD
Gliclazide—Rash—Epirubicin—bone cancer	0.000415	0.000624	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—bone cancer	0.000415	0.000623	CcSEcCtD
Gliclazide—Headache—Epirubicin—bone cancer	0.000413	0.00062	CcSEcCtD
Gliclazide—ABCC8—Metabolism—ENO2—bone cancer	0.00041	0.00124	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MMP9—bone cancer	0.000403	0.00122	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—bone cancer	0.000403	0.000605	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000402	0.00121	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—ENO2—bone cancer	0.000397	0.0012	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—bone cancer	0.000391	0.000588	CcSEcCtD
Gliclazide—Vomiting—Doxorubicin—bone cancer	0.000387	0.000582	CcSEcCtD
Gliclazide—Rash—Doxorubicin—bone cancer	0.000384	0.000577	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—bone cancer	0.000384	0.000577	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—MMP2—bone cancer	0.000383	0.00116	CbGpPWpGaD
Gliclazide—Headache—Doxorubicin—bone cancer	0.000382	0.000573	CcSEcCtD
Gliclazide—ABCC8—Metabolism—DHFR—bone cancer	0.00038	0.00115	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DHFR—bone cancer	0.000369	0.00111	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NDUFA12—bone cancer	0.000364	0.0011	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—bone cancer	0.000362	0.000544	CcSEcCtD
Gliclazide—ABCC8—Metabolism—GNA11—bone cancer	0.000355	0.00107	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—bone cancer	0.000345	0.00104	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GNA11—bone cancer	0.000345	0.00104	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000327	0.000987	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—bone cancer	0.000326	0.000984	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—bone cancer	0.000322	0.000973	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP3A4—bone cancer	0.000322	0.000973	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP3A4—bone cancer	0.000312	0.000944	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SPARC—bone cancer	0.000309	0.000933	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NT5C3A—bone cancer	0.000302	0.000911	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000298	0.0009	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SMO—bone cancer	0.000297	0.000897	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MMP9—bone cancer	0.000288	0.000869	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—GNA11—bone cancer	0.000283	0.000854	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTP1—bone cancer	0.000276	0.000832	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GNA11—bone cancer	0.000271	0.00082	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NT5C3A—bone cancer	0.000271	0.000818	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTP1—bone cancer	0.000267	0.000807	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL3—bone cancer	0.000256	0.000774	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—ATF1—bone cancer	0.000252	0.000762	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000247	0.000746	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL3—bone cancer	0.000246	0.000744	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—bone cancer	0.000232	0.000702	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TGFBR2—bone cancer	0.00021	0.000636	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IGF1R—bone cancer	0.000198	0.000598	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—bone cancer	0.000191	0.000578	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PLAU—bone cancer	0.000168	0.000508	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KIT—bone cancer	0.000144	0.000434	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—bone cancer	0.000143	0.000431	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—bone cancer	0.000138	0.000418	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—bone cancer	0.000135	0.000408	CbGpPWpGaD
Gliclazide—ALB—Metabolism—ENO2—bone cancer	0.000132	0.000399	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DHFR—bone cancer	0.000123	0.00037	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—ENO2—bone cancer	0.000119	0.000358	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GNA11—bone cancer	0.000115	0.000346	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MDM2—bone cancer	0.000113	0.000342	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DHFR—bone cancer	0.00011	0.000332	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—ENO2—bone cancer	0.000108	0.000327	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP3A4—bone cancer	0.000104	0.000314	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000103	0.000312	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GNA11—bone cancer	0.000103	0.000311	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DHFR—bone cancer	0.0001	0.000303	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—bone cancer	9.83e-05	0.000297	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MMP9—bone cancer	9.56e-05	0.000289	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GNA11—bone cancer	9.38e-05	0.000283	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP3A4—bone cancer	9.32e-05	0.000282	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.28e-05	0.00028	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTP1—bone cancer	8.88e-05	0.000268	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP3A4—bone cancer	8.5e-05	0.000257	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.46e-05	0.000256	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTP1—bone cancer	7.97e-05	0.000241	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—bone cancer	7.73e-05	0.000234	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTP1—bone cancer	7.27e-05	0.00022	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—bone cancer	6.76e-05	0.000204	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—bone cancer	6.49e-05	0.000196	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—bone cancer	4.6e-05	0.000139	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—bone cancer	4.13e-05	0.000125	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—bone cancer	3.77e-05	0.000114	CbGpPWpGaD
